The Consortium for Clarity in ADRD Research Through Imaging (CLARiTI)

Elizabeth C Mormino; Sarah A Biber; Annalise Rahman-Filipiak; Konstantinos Arfanakis; Lindsay Clark; Jeffrey L Dage; John A Detre; Bradford C Dickerson; Michael C Donohue; Steven Kecskemeti; Timothy J Hohman; William J Jagust; Dirk C Keene; Walter Kukull; Swati R Levendovszky; Howie Rosen; Paul M Thompson; Victor L Villemagne; David A Wolk; Ozioma C Okonkwo; Gil D Rabinvovici; Monica Rivera-Mindt; Tatiana Foroud; Sterling C Johnson

doi:10.1002/alz.14383

The Consortium for Clarity in ADRD Research Through Imaging (CLARiTI)

Alzheimers Dement. 2024 Nov 26. doi: 10.1002/alz.14383. Online ahead of print.

Authors

Elizabeth C Mormino^{1

2}, Sarah A Biber³, Annalise Rahman-Filipiak⁴, Konstantinos Arfanakis⁵, Lindsay Clark⁶, Jeffrey L Dage^{7

8}, John A Detre⁹, Bradford C Dickerson¹⁰, Michael C Donohue^{11

12}, Steven Kecskemeti⁶, Timothy J Hohman¹³, William J Jagust^{14

15}, Dirk C Keene¹⁶, Walter Kukull^{3

17}, Swati R Levendovszky¹⁸, Howie Rosen¹⁹, Paul M Thompson²⁰, Victor L Villemagne²¹, David A Wolk⁹, Ozioma C Okonkwo⁶, Gil D Rabinvovici¹⁹, Monica Rivera-Mindt^{22

23}, Tatiana Foroud²⁴, Sterling C Johnson⁶

Affiliations

¹ Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Palo Alto, California, USA.
² Wu Tsai Neurosciences Institute, Stanford University School of Medicine, Cogen Facility, Stanford, California, USA.
³ National Alzheimer's Coordinating Center, University of Washington, Seattle, Washington, USA.
⁴ Department of Psychiatry, University of Michigan, Ann Arbor, Michigan, USA.
⁵ Department of Biomedical Engineering, Illinois Tech, Chicago, Illinois, USA.
⁶ Department of Medicine, University of Wisconsin School of Medicine and Public Health, Health Sciences Learning Center, Madison, Wisconsin, USA.
⁷ Department of Neurology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
⁸ Stark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis, Indiana, USA.
⁹ Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
¹⁰ Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
¹¹ Department of Neurology, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
¹² Alzheimer's Therapeutic Research Institute (ATRI), University of Southern California, San Diego, California, USA.
¹³ Department of Neurology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
¹⁴ Department of Epidemiology, School of Public Health, University of California, Berkeley, California, USA.
¹⁵ Helen Wills Neuroscience Institute, University of California, Berkeley, California, USA.
¹⁶ Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA.
¹⁷ Department of Epidemiology, University of Washington, Seattle, Washington, USA.
¹⁸ Department of Radiology, University of Washington, Seattle, Washington, USA.
¹⁹ Department of Neurology, University of California, San Francisco, California, USA.
²⁰ Department of Ophthalmology, Psychiatry and the Behavioral Sciences, Radiology, Psychiatry, and Engineering, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
²¹ Department of Psychiatry, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
²² Department of Psychology, Fordham University, Bronx, New York, USA.
²³ Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
²⁴ Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana, USA.

PMID: 39588767
DOI: 10.1002/alz.14383

Abstract

The presence of multiple pathologies is the largest predictor of dementia. A major gap in the field is the in vivo detection of mixed pathologies and their antecedents. The Alzheimer's Disease Research Centers (ADRCs) are uniquely positioned to address this gap. The ADRCs longitudinally follow ≈ 17,000 participants, ranging from cognitively unimpaired to dementia, arising from Alzheimer's disease (AD) and related dementias (ADRD; e.g., AD, Lewy body disorders, vascular). Motivated by the Alzheimer's Disease Neuroimaging Initiative's (ADNI) impact, the ADRC Consortium for Clarity in ADRD Research Through Imaging (CLARiTI) was formed. Leveraging existing ADRC infrastructure, CLARiTI will integrate standardized imaging and plasma collection to characterize mixed pathologies and use community-engaged research methods to ensure that ≥ 25% of the sample is from underrepresented populations (e.g., ethnoculturally minoritized, low education). The resulting ADRD profiles, within a more diverse sample, will provide key resources for ADRCs and an unprecedented, more generalizable publicly available imaging-plasma dataset. HIGHLIGHTS: In vivo detection of mixed pathologies is critical for Alzheimer's disease and related dementias research. The Alzheimer's Disease Research Centers (ADRCs) are uniquely positioned to address gaps related to mixed pathologies. The ADRC Consortium for Clarity in ADRD Research Through Imaging (CLARiTI) will enhance this national program by adding standardized imaging and plasma collection to existing ADRC infrastructure. This effort will provide key resources for ADRCs and an unprecedented publicly available imaging-plasma-neuropath dataset.

Keywords: Alzheimer's disease; biomarkers; magnetic resonance imaging; neuroimaging; pathology; plasma markers; positron emission tomography.

Publication types

Review

Grants and funding

U01-AG082350/GF/NIH HHS/United States